BioWorld MedTech

Nov. 16, 2015

Mindray merger a precursor to U.S. stock exchange delisting, return to private status

HONG KONG — One of the biggest Chinese medical device companies is undergoing a $3 billion delisting from the U.S. market as it paves the way to head back to its home market and the possibility of more access to investment. Read More

CT colongraphy is again gaining traction on Hill

Mimedx says market overreacted to FDA's recent HCT/P guidance

Colombia defining technological device evaluation guidelines

M&A activity increases as industry gets personal

AHA, Google Life Sciences enter $50M research collaboration

Products

Thermo Fisher authorizes $1 billion share repurchase

Keeping you up to date on recent developments in Neurology

Today's news in brief

BioWorld

BioWorld briefs for June 12, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

Pre-disease plasma signature may help redefine lung cancer risk

BioWorld

Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...

Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis

BioWorld

Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...

Ethyreal launches to treat the underlying cause of Graves’, TED

BioWorld

Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...